Skip to main content

MoneyWorks4Me

Brooks Laboratories acquires 44.33% stake in SteriBrooks Penems

18 Sep 2020 Evaluate

Brooks Laboratories has subscribed to 7963 equity shares at the face value of Rs 10 each of SteriBrooks Penems, amounting to 44.33% of the post issue paid-up shares capital of SteriBrooks. The object of the said acquisition is to build a robust carbapenem business with integrated manufacturing capabilities.  

Brooks Laboratories has wide range of products catering to critical care segment in Parental Section like Beta Lactam, Cephalosporin & General dry powder Injectables, Ampoules and Liquid vials.

Peers
Company Name CMP
Sun Pharma. Inds. 1890.85
Dr. Reddys Labs. 1376.25
Cipla 1410.40
Lupin 2014.30
Zydus Lifesciences 1190.10
View more..